Sudeep Pharma’s Q1 FY27: Growth holds up, execution becomes the story

Sudeep Pharma Limited started FY27 with a strong quarter, despite a choppy operating environment. Consolidated revenue from operations rose 27% year on year to INR 158.3 crores in Q1 FY27, up from INR 124.9 crores in Q1 FY26. EBITDA increased 25% to INR 54.9 crores and profit after tax grew 30% to INR 40.6 crores.

Profitability remained healthy. EBITDA margin stood at 34.7% versus 35.1% a year ago, while PAT margin improved to 25.6% from 25.0%. Management attributed the performance to broad based execution across the Pharma, Food and Nutrition business and the Speciality Ingredients portfolio, supported by ongoing operational excellence initiatives and manufacturing efficiency improvement.

The quarter also carried its share of operational stress. Management cited geopolitical uncertainty, supply chain disruption, intermittent gas supply constraints, elevated logistics costs, and continued container shortages on key routes. In addition, the company highlighted a sharp rise in sulfur prices that drove phosphoric acid prices up by about 50% during the quarter. Management said it implemented price pass through actions during Q1 and expects these to largely offset the input cost impact in Q2.

Q1 FY27 performance in numbers

The company’s quarterly financial trajectory remained robust, with both top line and profit growth outpacing the previous year.

On the mix side, the revenue split in the investor presentation showed Pharma and Food Nutrition at 66% and Speciality Ingredients at 34% in Q1 FY27. Export contribution also increased to 55% in Q1 FY27 compared with 49% in Q1 FY26.

Segment trends: PFN strong, speciality disrupted, NSS still in a tough Europe

Management’s commentary suggested that the core Pharma, Food and Nutrition segment delivered strong growth, with the director stating that PFN revenue rose 31% year on year. Importantly, the growth was described as largely volume driven. Management said only around 3% of the growth was driven by currency change, and that most of the phosphate related price pass through would reflect in Q2.

Two product themes stood out in the call.

First, the phosphate portfolio. Management said customer demand for phosphates continues to exceed current manufacturing capacity. That kind of statement is typically a strong indicator for near term revenue visibility, especially when it comes from an established product family with repeat customers.

Second, the AbsorBis Bisglycinates portfolio. The company said Q1 FY27 sales have already surpassed the total sales of the entire previous financial year for this portfolio. It also highlighted two major approvals from large North American customers. Management said it is scaling up supplies and noted it is behind schedule on deliveries, which implies that the ramp up is constrained more by supply and execution than demand.

Speciality Ingredients grew 19% year on year in Q1 FY27, but management acknowledged it was below historical growth levels. The reason cited was a temporary operational constraint due to LPG supply shortage during April and the first half of May. Production ran at significantly lower utilization levels during this period. Supplies were later secured, though at a higher cost, and management stated that operations have normalized in Q2.

NSS, the European premix business where Sudeep holds 85%, continued to face a weak operating environment in Europe. Management linked the slowdown to elevated energy costs and subdued industrial activity. It also clarified that NSS’s customer ordering patterns were impacted due to a large infant formula customer scaling down operations in Ireland, which delayed buying even when purchase orders existed.

Still, integration efforts were described as progressing across procurement, supply chain, commercial operations, and customer engagement. Management also said a new business head joined in June and has initiated approvals with five customers in infant nutrition and dairy segments, with an active pipeline of 12 customer projects. The company expects NSS recovery to be more gradual than its India speciality business and stated a target for NSS to deliver similar margins as the core speciality ingredients business by FY28.

Capacity and capex: Greenfield ramp and a new battery materials engine

Sudeep’s growth roadmap is being carried by two major initiatives: a greenfield expansion for the core excipients and minerals business, and a battery materials project under Sudeep Advanced Materials.

Greenfield expansion at Nandesari

The investor presentation described the upcoming greenfield expansion at Nandesari GIDC, Vadodara, with a total capex of about INR 150 crores and capacity of 51,200 MT annually. The facility is intended for pharmaceutical excipients, actives, and food and nutrition minerals.

On the call, management said internal validation is completed and customer validation is in progress. It also stated the facility is already approved to supply into the food and nutrition category, and is undergoing FDA approval, which it expects in the quarter referenced in the call.

Management also suggested that near term growth in PFN from existing capacity is limited to marginal debottlenecking, and that further growth would need the greenfield capacity. In response to a question on sustainability of PFN growth, management said it expects to wait for the greenfield to be commissioned in Q3 to add incremental growth.

Battery grade iron phosphate at Dahej

Sudeep Advanced Materials is positioned as a non China supplier for battery grade iron phosphate precursor. The investor presentation stated a battery materials plant is being set up at Dahej, Gujarat, with a project cost of about INR 300 crores, funded via internal accruals plus debt. Phase 1 is planned at 25,000 MT, with longer term scale up targets of 65,000 MT and 105,000 MT.

In the call, management said construction remains on schedule and it continues to target commissioning of Phase 1 by April 2027. Deliveries of major long lead equipment are expected to be completed by October, and statutory approvals are progressing in line with schedule.

What added credibility was the disclosure of customer qualification funnel metrics. Management said 21 customers are at lab validation, 16 have progressed to pilot scale evaluation, and 7 have completed pre commercial or commercial validation and are in active off take discussions. It also said it signed two additional strategic MoUs during the quarter with leading South Korean cathode active material manufacturers and their cell manufacturing partners.

Management further stated it expects to conclude two significant binding off take agreements later in the year, subject to which it could accelerate Phase 2 and Phase 3 planning. It also said it has begun evaluating a further expansion from 100 KTPA to 200 KTPA and clarified that the Dahej site can support 200 KTPA. Beyond that, a new location would be needed.

A key strategic disclosure was related to supply chain compliance. In response to a question on China dependence, management said it will not source phosphoric acid from China as that is a prerequisite for FEOC compliance for supplying into the US market. It also said phosphoric acid is already its largest raw material and that it sources from India and imports from three other countries, excluding China.

What to track from here

Sudeep Pharma’s Q1 FY27 message was consistent. Growth remained strong, margins held up, and the company continues to invest behind new capacity and new product platforms. But the quarter also revealed how execution risks can appear in operational form, from LPG shortages to European demand softness and raw material volatility.

For investors, the near term watch items are clear. The pace of greenfield customer and regulatory approvals, including the expected FDA approval timeline, will shape PFN growth through FY27 and FY28. Speciality Ingredients should revert to its historical trajectory if production normalization sustains through Q2, while NSS remains dependent on Europe’s recovery and the company’s ability to diversify its customer base and end markets.

The battery materials project is the longer duration lever, and management has provided both a commissioning timeline and measurable commercial funnel progress. The credibility of the battery thesis will increasingly depend on the company’s ability to convert off take discussions into binding agreements and execute the Phase 1 ramp up without delays.

Overall, Q1 FY27 positioned Sudeep Pharma as a company moving from a strong speciality chemicals base into a more diversified growth profile, with capital discipline and execution as the main drivers of the next phase.